RecruitingPhase 3NCT06427395
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zydus Therapeutics Inc.
- Principal Investigator
- Deven ParmarZydus Therapeutics Inc.
- Intervention
- Saroglitazar Magnesium 1 mg(drug)
- Enrollment
- 150 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (28)
- Zydus US013, Los Angeles, California, United States
- Zydus US011, Pasadena, California, United States
- Zydus US043, Sacramento, California, United States
- Zydus US022, Aurora, Colorado, United States
- Zydus US037, New Haven, Connecticut, United States
- Zydus US027, Jacksonville, Florida, United States
- Zydus US006, Lakewood Rch, Florida, United States
- Zydus US005, Miami, Florida, United States
- Zydus US020, Marietta, Georgia, United States
- Zydus US001, Indianapolis, Indiana, United States
- Zydus US035, Rochester, New York, United States
- Zydus US002, Charlotte, North Carolina, United States
- Zydus US042, Houston, Texas, United States
- Zydus US031, Murray, Utah, United States
- Zydus US016, Charlottesville, Virginia, United States
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06427395 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta